$558 Million is the total value of Medicxi Ventures Management (Jersey) Ltd's 6 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CNTA | New | CENTESSA PHARMACEUTICALS PLCsponsored ads | $398,090,000 | – | 17,923,892 | +100.0% | 71.34% | – |
| PHAT | PHATHOM PHARMACEUTICALS INC | $69,997,000 | -9.9% | 2,067,861 | 0.0% | 12.54% | -72.3% | |
| PCVX | VAXCYTE INC | $42,489,000 | +14.0% | 1,887,478 | 0.0% | 7.62% | -64.9% | |
| MRUS | MERUS N V | $33,712,000 | +0.9% | 1,600,000 | 0.0% | 6.04% | -69.0% | |
| CMPI | CHECKMATE PHARMACEUTICALS IN | $8,950,000 | -50.9% | 1,501,716 | 0.0% | 1.60% | -84.9% | |
| OBSV | OBSEVA SA | $4,757,000 | -6.8% | 1,570,000 | 0.0% | 0.85% | -71.3% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Francesco De Rubertis #1
- Kevin Stuart Johnson #2
- Michele Ollier #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-03
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PHATHOM PHARMACEUTICALS INC | 16 | Q3 2023 | 69.8% |
| MERUS N V | 16 | Q3 2023 | 25.3% |
| VAXCYTE INC | 14 | Q3 2023 | 44.5% |
| OBSEVA SA | 12 | Q3 2022 | 5.7% |
| CENTESSA PHARMACEUTICALS PLC | 10 | Q3 2023 | 71.3% |
| AURA BIOSCIENCES INC | 8 | Q3 2023 | 22.9% |
| CHECKMATE PHARMACEUTICALS IN | 8 | Q2 2022 | 12.7% |
| NEWAMSTERDAM PHARMA COMPANY | 4 | Q3 2023 | 11.4% |
| SYNTHORX INC | 1 | Q4 2019 | 43.1% |
View Medicxi Ventures Management (Jersey) Ltd's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-15 |
| 13F-HR | 2024-02-01 |
| 3 | 2024-01-26 |
| 13F-HR | 2023-10-18 |
| 13F-HR | 2023-07-19 |
| 13F-HR | 2023-04-27 |
| 13F-HR | 2023-01-31 |
| 13F-HR | 2022-10-25 |
| 13F-HR/A | 2022-08-03 |
| 13F-HR | 2022-08-03 |
View Medicxi Ventures Management (Jersey) Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.